<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.4.5</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-2973</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Ближайшие результаты лечения стафилококковой перипротезной инфекции тазобедренного сустава с использованием комбинированной терапии антибиотиками и бактериофагами</article-title><trans-title-group xml:lang="en"><trans-title>Short-term results of treatment of staphylococcal periprosthetic hip joint infection with combined antibiotics and bacteriophages treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4084-4956</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фёдоров</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> врач травматолог-ортопед травматолого-ортопедического отделения № 2</p><p>630091, г. Новосибирск, ул. Фрунзе, 17, Россия</p></bio><bio xml:lang="en"><p> Orthopedic Traumatologist at the Trauma-Orthopedic Department N 2</p><p> Frunze str. 17, Novosibirsk 630091, Russian Federation </p></bio><email xlink:type="simple">evgeniifedorov1987@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0074-8062</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кретьен</surname><given-names>С. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kretien</surname><given-names>S. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p> заведующая бактериологической лабораторией</p><p>630091, г. Новосибирск, ул. Фрунзе, 17, Россия</p></bio><bio xml:lang="en"><p> Head of the Bacteriological Laboratory</p><p> Frunze str. 17, Novosibirsk 630091, Russian Federation </p></bio><email xlink:type="simple">Skretien@niito.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5599-3925</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самохин</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Samokhin</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p> кандидат медицинских наук, старший научный сотрудник лабораторно-экспериментального отдела</p><p>630091, г. Новосибирск, ул. Фрунзе, 17, Россия</p></bio><bio xml:lang="en"><p> Cand. Sc. (Med.), Senior Research Officer at the Laboratory and Experimental Department</p><p> Frunze str. 17, Novosibirsk 630091, Russian Federation </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1687-8278</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тикунова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tikunova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> заведующая лабораторией молекулярной биологии</p><p>630090, г. Новосибирск, пр. Ак. Лаврентьева, 8, Россия</p></bio><bio xml:lang="en"><p> Head of the Laboratory of Molecular Biology, Institute of Chemical Biology and Fundamental Medicine</p><p>Lavrentyeva av. 8, Novosibirsk 630090, Russian Federation </p></bio><email xlink:type="simple">tikunova@niboch.nsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9231-5891</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корыткин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Korytkin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> кандидат медицинских наук, директор</p><p>630091, г. Новосибирск, ул. Фрунзе, 17, Россия</p></bio><bio xml:lang="en"><p> Cand. Sc. (Med.), Director</p><p> Frunze str. 17, Novosibirsk 630091, Russian Federation </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8997-7330</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> доктор медицинских наук, начальник научно-исследовательского отделения эндопротезирования и эндоскопической хирургии суставов</p><p>630091, г. Новосибирск, ул. Фрунзе, 17, Россия</p></bio><bio xml:lang="en"><p> Dr. Sc. (Med.), Head of the Endoprosthetics and Endoscopic Joint Surgery Research Department</p><p> Frunze str. 17, Novosibirsk 630091, Russian Federation </p></bio><email xlink:type="simple">pavlovdoc@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Новосибирский научно-исследовательский институт травматологии и ортопедии им. Я.Л. Цивьяна» Минздрава России</institution></aff><aff xml:lang="en"><institution>Novosibirsk Research Institute of Traumatology and Orthopedics</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН Институт химической биологии и фундаментальной медицины СО РАН</institution></aff><aff xml:lang="en"><institution>Siberian Branch of the Russian Academy of Sciences</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2021</year></pub-date><volume>6</volume><issue>4</issue><fpage>50</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фёдоров Е.А., Кретьен С.О., Самохин А.Г., Тикунова Н.В., Корыткин А.А., Павлов В.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Фёдоров Е.А., Кретьен С.О., Самохин А.Г., Тикунова Н.В., Корыткин А.А., Павлов В.В.</copyright-holder><copyright-holder xml:lang="en">Fedorov E.A., Kretien S.O., Samokhin A.G., Tikunova N.V., Korytkin A.A., Pavlov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/2973">https://www.actabiomedica.ru/jour/article/view/2973</self-uri><abstract><p>Частота инфекционных осложнений после первичной имплантации эндопротеза тазобедренного сустава составляет 0,5–3 %, а в случае реэндопротезирования риск перипротезной инфекции может достигать 30 %. Также не стоит забывать о высоком проценте (16–20 %) рецидива перипротезной инфекции тазобедренного сустава, который приводит к неудовлетворительному результату лечения вплоть до ампутации конечности или даже смерти пациента. Причинами рецидива инфекционного процесса могут послужить антибиотикорезистентность и антибиотикотолерантность микроорганизмов, а также способность микроорганизмов образовывать на имплантатах биоплёнки. В этой связи существует постоянная потребность поиска альтернативных средств антимикробной терапии, а также выбора оптимальных путей их доставки и депонирования, что имеет прикладное значение при выполнении хирургических вмешательств в травматологии и ортопедии для защиты имплантируемой конструкции от возможной инфекции области хирургического вмешательства. В настоящее время существует эффективный метод борьбы с бактериальными инфекциями, с приобретённой антибиотикорезистентностью и антибиотикотолерантностью, который заключается в применении естественных вирусов, инфицирующих бактерии, – бактериофагов. Вышесказанное позволяет предполагать более эффективное подавление перипротезной инфекции, включая бактериальные клетки-персистеры, отклоняющиеся от действия антибиотиков и, как правило, ассоциированные с биоплёнками. При совместном использовании антибиотиков и фагов применение бактериофагов предопределяет эффективность лечения. В случае использования подобранных по чувствительности бактериофагов при лечении перипротезной инфекции отмечено статистически значимое (p = 0,030) существенное уменьшение частоты рецидивов инфекции (с 31 до 4,5 %). Использование литических бактериофагов в травматологии и ортопедии представляет большой интерес, так как бактериофаги способны лизировать антибиотикорезистентные штаммы бактерий, а также бактерии, которые находятся в биоплёнке. Клиническое исследование с применением одноэтапной ревизии и одновременного применения антибиотиков и фагов при лечении глубокой перипротезной инфекции эндопротеза тазобедренного сустава с последующим наблюдением за исходом лечения данной инфекции в течение 12 месяцев продемонстрировало высокую эффективность применения бактериофагов.</p></abstract><trans-abstract xml:lang="en"><p>Infectious complications after primary implantation of the hip joint are 0.5–3 %, and in the case of re-endoprosthetics, the risk of periprosthetic infection can reach 30 %. Also, we should not forget about the high percentage (16–20 %) of recurrence of periprosthetic infection of the hip joint, which leads to an unsatisfactory result of treatment up to amputation of a limb or even death of the patient. The reasons for the recurrence of the infectious process can be antibiotic resistance and antibiotic tolerance of microorganisms, as well as the ability of microorganisms to form biofilms on implants. In this regard, there is a constant need to search for alternative means of antimicrobial therapy, as well as to select the optimal ways of their delivery and deposition, which is of practical importance when performing surgical interventions in traumatology and orthopedics to protect the implantable structure from possible infection of the surgical site. One of the methods currently available to combat bacterial infections acquired antibiotic resistance and antibiotic tolerance is the use of natural viruses that infect bacterial bacteriophages. The above suggests a more effective suppression of periprosthetic infection, including persisters that deviate from antibiotics. It is, as a rule, associated with biofilms if used in conjunction with antibiotics and phages, when the use of bacteriophages predetermines the effectiveness of treatment. With the use of sensitive bacteriophages in the treatment of periprosthetic infections, a significant (p = 0.030) reduction in the rate of recurrence of infection (from 31 to 4.5 %) was observed. The use of lytic bacteriophages in traumatology and orthopedics is of great interest for phagotherapy of infections caused by antibiotic-resistant and biofilm-forming strains of bacteria. A clinical study using a single-stage surgical revision with simultaneous application of antibiotics and phages in the treatment of deep periprosthesis infection of the hip joint endoprosthesis, followed by 12 months follow-up for periprosthetic infection recurrence, demonstrated the effectiveness of the use of combined antibiotic and bacteriophages treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>стафилококк</kwd><kwd>бактериофаг</kwd><kwd>перипротезная инфекция</kwd><kwd>эндопротез</kwd><kwd>тазобедренный сустав</kwd></kwd-group><kwd-group xml:lang="en"><kwd>staphylococcus</kwd><kwd>bacteriophage</kwd><kwd>periprosthetic infection</kwd><kwd>endoprosthesis</kwd><kwd>hip joint</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fuchs M, von Roth P, Pfitzner T, Kopf S, Sass FA. Contamination of irrigation fluid during primary total knee arthroplasty. J Am Acad Orthop Surg Glob Res Rev. 2018; 2(5): е027. doi: 10.5435/JAAOSGlobal-D-17-00027</mixed-citation><mixed-citation xml:lang="en">Fuchs M, von Roth P, Pfitzner T, Kopf S, Sass FA. Contamination of irrigation fluid during primary total knee arthroplasty. J Am Acad Orthop Surg Glob Res Rev. 2018; 2(5): е027. doi: 10.5435/JAAOSGlobal-D-17-00027</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Roth VR, Mitchell R, Vachon J, Alexandre S, Amaratunga K, Smith S, et al. Periprosthetic infection following primary hip and knee arthroplasty: the impact of limiting the postoperative surveillance period. Infect Control Hosp Epidemiol. 2017; 38(2): 147-153. doi: 10.1017/ice.2016.256</mixed-citation><mixed-citation xml:lang="en">Roth VR, Mitchell R, Vachon J, Alexandre S, Amaratunga K, Smith S, et al. Periprosthetic infection following primary hip and knee arthroplasty: the impact of limiting the postoperative surveillance period. Infect Control Hosp Epidemiol. 2017; 38(2): 147-153. doi: 10.1017/ice.2016.256</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Grammatopoulos G, Kendrick B, McNally M, Athanasou NA, Atkins B, McLardy-Smith P, et al. Outcome following debridement, antibiotics, and implant retention in hip periprosthetic joint infection – An 18-year experience. J Arthroplasty. 2017; 32(7): 2248-2255. doi: 10.1016/j.arth.2017.02.066</mixed-citation><mixed-citation xml:lang="en">Grammatopoulos G, Kendrick B, McNally M, Athanasou NA, Atkins B, McLardy-Smith P, et al. Outcome following debridement, antibiotics, and implant retention in hip periprosthetic joint infection – An 18-year experience. J Arthroplasty. 2017; 32(7): 2248-2255. doi: 10.1016/j.arth.2017.02.066</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Akgün D, Müller M, Perka C, Winkler T. An often-unrecognized entity as cause of recurrent infection after successfully treated two-stage exchange arthroplasty: hematogenous infection. Arch Orthop Trauma Surg. 2018; 138(9): 1199-1206. doi: 10.1007/s00402-018-2972-3</mixed-citation><mixed-citation xml:lang="en">Akgün D, Müller M, Perka C, Winkler T. An often-unrecognized entity as cause of recurrent infection after successfully treated two-stage exchange arthroplasty: hematogenous infection. Arch Orthop Trauma Surg. 2018; 138(9): 1199-1206. doi: 10.1007/s00402-018-2972-3</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jhan SW, Lu YD, Lee MS, Lee CH, Wang JW, Kuo FC. The risk factors of failed reimplantation arthroplasty for periprosthetic hip infection. BMC Musculoskelet. Disord. 2017; 18(1): 1-7. doi: 10.1186/s12891-017-1622-1</mixed-citation><mixed-citation xml:lang="en">Jhan SW, Lu YD, Lee MS, Lee CH, Wang JW, Kuo FC. The risk factors of failed reimplantation arthroplasty for periprosthetic hip infection. BMC Musculoskelet. Disord. 2017; 18(1): 1-7. doi: 10.1186/s12891-017-1622-1</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shahi A, Tan TL, Chen AF, Maltenfort MG, Parvizi J. Inhospital mortality in patients with periprosthetic joint infection. J Arthroplasty. 2017; 32(3): 948-952. doi: 10.1016/j.arth.2016.09.027</mixed-citation><mixed-citation xml:lang="en">Shahi A, Tan TL, Chen AF, Maltenfort MG, Parvizi J. In-hospital mortality in patients with periprosthetic joint infection. J Arthroplasty. 2017; 32(3): 948-952. doi: 10.1016/j.arth.2016.09.027</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Son MS, Lau E, Parvizi J, Mont MA, Bozic KJ, Kurtz S. What are the frequency, associated factors, and mortality of amputation and arthrodesis after a failed infected TKA? Clin Orthop Relat Res. 2017; 475(12): 2905-2913. doi: 10.1007/s11999-017-5285-x</mixed-citation><mixed-citation xml:lang="en">Son MS, Lau E, Parvizi J, Mont MA, Bozic KJ, Kurtz S. What are the frequency, associated factors, and mortality of amputation and arthrodesis after a failed infected TKA? Clin Orthop Relat Res. 2017; 475(12): 2905-2913. doi: 10.1007/s11999-017-5285-x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Canham CD, Walsh CP, Incavo SJ. Antibiotic impregnated total femur spacers: A technical tip. Arthroplast Today. 2018; 4(1): 65-70. doi: 10.1016/j.artd.2017.06.001</mixed-citation><mixed-citation xml:lang="en">Canham CD, Walsh CP, Incavo SJ. Antibiotic impregnated total femur spacers: A technical tip. Arthroplast Today. 2018; 4(1): 65-70. doi: 10.1016/j.artd.2017.06.001</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kliushin NM, Ababkov YV, Ermakov AM, Malkova TA. Modified Girdlestone arthroplasty and hip arthrodesis using the Ilizarov external fixator as a salvage method in the management of severely infected total hip replacement. Indian J Orthop. 2016; 50(1): 16-24. doi: 10.4103/0019-5413.173513</mixed-citation><mixed-citation xml:lang="en">Kliushin NM, Ababkov YV, Ermakov AM, Malkova TA. Modified Girdlestone arthroplasty and hip arthrodesis using the Ilizarov external fixator as a salvage method in the management of severely infected total hip replacement. Indian J Orthop. 2016; 50(1): 16-24. doi: 10.4103/0019-5413.173513</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Тикунова Н.В., Власов В.В. Бактериофаги – враги наших врагов. Наука из первых рук. 2013; 2(50): 58-69.</mixed-citation><mixed-citation xml:lang="en">Тикунова Н.В., Власов В.В. Бактериофаги – враги наших врагов. Наука из первых рук. 2013; 2(50): 58-69.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017; 249: 100-133. doi: 10.1016/j.cis.2017.05.014</mixed-citation><mixed-citation xml:lang="en">Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017; 249: 100-133. doi: 10.1016/j.cis.2017.05.014</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Самохин А.Г., Козлова Ю.Н., Корнеев Д.В., Таранов О.С., Фёдоров Е.А., Павлов В.В., и др. Экспериментальное исследование антибактериальной активности литического стафилококкового бактериофага ph20 и литического бактериофага синегнойной палочки ph57 при моделировании их импрегнации в ортопедические полимерные конструкции из полиметилметакрилата (костного цемента). Вестник Российской академии медицинских наук. 2018; 73(1): 59-68. doi: 10.15690/vramn905</mixed-citation><mixed-citation xml:lang="en">Samokhin AG, Kozlova JN, Korneev DV, Taranov OS, Fedorov EA, Pavlov VV, et al. Experimental study of the antibacterial activity of the lytic Staphylococcus aureus bacteriophage ph20 and lytic Pseudomonas aeruginosa bacteriophage ph57 during modelling of its impregnation into poly(methylmetacrylate) orthopedic implants (bone cement). Annals of the Russian academy of medical sciences. 2018; 73(1): 59-68. (In Russ.). doi: 10.15690/vramn905</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 2013; 95-B(11): 1450-1452. doi: 10.1302/0301-620X.95B11.33135</mixed-citation><mixed-citation xml:lang="en">Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 2013; 95-B(11): 1450-1452. doi: 10.1302/0301-620X.95B11.33135</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Parvizi J, Fassihi SC, Enayatollahi MA. Diagnosis of periprosthetic joint infection following hip and knee arthroplasty. Orthop Clin North Am. 2016; 47(3): 505-515. doi: 10.1016/j.ocl.2016.03.001</mixed-citation><mixed-citation xml:lang="en">Parvizi J, Fassihi SC, Enayatollahi MA. Diagnosis of periprosthetic joint infection following hip and knee arthroplasty. Orthop Clin North Am. 2016; 47(3): 505-515. doi: 10.1016/j.ocl.2016.03.001</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. J Bone Joint Surg Am. 1996; 78(4): 512-523. doi: 10.2106/00004623-199604000-00005</mixed-citation><mixed-citation xml:lang="en">Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. J Bone Joint Surg Am. 1996; 78(4): 512-523. doi: 10.2106/00004623-199604000-00005</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Павлов В.В., Самохин А.Г., Козлова Ю.Н., Федоров Е.А., Прохоренко В.М., Кретьен С.О., и др. Способ оценки эффективности фаготерапии при лечении хирургических инфекций: Патент № 2624511 Рос. Федерация; МПК G01N 33/48 (2006.01), C12Q 1/04 (2006.01). Заявл. 03.08.2016; опубл. 04.07.2017. Бюл. № 19.</mixed-citation><mixed-citation xml:lang="en">Pavlov VV, Samokhin AG, Kozlova YuN, Fedorov EA, Prokhorenko VM, Kretien SO, et al. Method for assessing the effectiveness of phage therapy in the treatment of surgical infections: Patent N 2624511 of the Russian Federation. 2017; (19). (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. Chapman and Hall/CRC; 2017</mixed-citation><mixed-citation xml:lang="en">Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. Chapman and Hall/CRC; 2017</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Самохин А.Г., Фёдоров Е.А., Козлова Ю.Н., Тикунова Н.В., Павлов В.В., Морозова В.В., и др. Применение литических бактериофагов при хирургическом лечении парапротезной инфекции эндопротеза тазобедренного сустава (пилотное исследование). Современные проблемы науки и образования. 2016; 6: 209. URL: https://www.science-education.ru/ru/article/view?id=25851 [Дата доступа: 02.09.2020]. doi: 10.17513/spno.25851</mixed-citation><mixed-citation xml:lang="en">Samokhin AG, Fedorov EA, Kozlova YuN, Tikunova NV, Pavlov VV, Morozova VV, et al. Application of lytic bacteriophages in surgical treatment of paraprosthetic infection of a hip joint endoprosthesis (pilot study). Modern problems of science and education. 2016; 6: 209. URL: https://www.science-education.ru/ru/article/view?id=25851 [Date of access: 02.09.2020]. (In Russ.). doi: 10.17513/spno.25851</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lora-Tamayo J, Euba G, Cobo J, Horcajada JP, Soriano A, Sandoval E, et al. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: A randomised clinical trial. Int J Antimicrob Agents. 2016; 48(3): 310-316. doi: 10.1016/j.ijantimicag.2016.05.021</mixed-citation><mixed-citation xml:lang="en">Lora-Tamayo J, Euba G, Cobo J, Horcajada JP, Soriano A, Sandoval E, et al. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: A randomised clinical trial. Int J Antimicrob Agents. 2016; 48(3): 310-316. doi: 10.1016/j.ijantimicag.2016.05.021</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012; 56(11): 5626-5632. doi: 10.1128/AAC.00038-12</mixed-citation><mixed-citation xml:lang="en">Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012; 56(11): 5626-5632. doi: 10.1128/AAC.00038-12</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Божкова С.А., Касимова А.Р., Тихилов Р.М., Полякова Е.М., Рукина А.Н., Шабанова В.В., и др. Неблагоприятные тенденции в этиологии ортопедической инфекции: результаты 6-летнего мониторинга структуры и резистентности ведущих возбудителей. Травматология и ортопедия России. 2018; 24(4): 20-31. doi: 10.21823/2311-2905-2018-24-4-20-31</mixed-citation><mixed-citation xml:lang="en">Bozhkova SA, Kasimova AR, Tikhilov RM, Polyakova EM, Rukina AN, Shabanova VV, et al. Adverse trends in the etiology of orthopedic infection: results of 6-year monitoring of the structure and resistance of leading pathogens. Traumatology and Orthopedics of Russia. 2018; 24(4): 20-31. (In Russ.). doi: 10.21823/2311-2905-2018-24-4-20-31</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mullen A, Wieland HJ, Wieser ES, Spannhake EW, Marinos RS. Perioperative participation of orthopedic patients and surgical staff in a nasal decolonization intervention to reduce Staphylococcus spp. surgical site infections. Am J Infect Control. 2017; 45(5): 554-556. doi: 10.1016/j.ajic.2016.12.021</mixed-citation><mixed-citation xml:lang="en">Mullen A, Wieland HJ, Wieser ES, Spannhake EW, Marinos RS. Perioperative participation of orthopedic patients and surgical staff in a nasal decolonization intervention to reduce Staphylococcus spp. surgical site infections. Am J Infect Control. 2017; 45(5): 554-556. doi: 10.1016/j.ajic.2016.12.021</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Rosteius T, Jansen O, Fehmer T, Baecker H, Citak M, Schildhauer TA, et al. Evaluating the microbial pattern of periprosthetic joint infections of the hip and knee. J Med Microbiol. 2018; 67(11): 1608-1613. doi: 10.1099/jmm.0.000835</mixed-citation><mixed-citation xml:lang="en">Rosteius T, Jansen O, Fehmer T, Baecker H, Citak M, Schildhauer TA, et al. Evaluating the microbial pattern of periprosthetic joint infections of the hip and knee. J Med Microbiol. 2018; 67(11): 1608-1613. doi: 10.1099/jmm.0.000835</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gorski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs. 2009; 10(8): 766-774.</mixed-citation><mixed-citation xml:lang="en">Gorski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs. 2009; 10(8): 766-774.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12): 591-595. doi: 10.1016/j.tibtech.2010.08.001</mixed-citation><mixed-citation xml:lang="en">Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12): 591-595. doi: 10.1016/j.tibtech.2010.08.001</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Morozova V, Kozlova Y, Shedko E, Babkin I, Kurilshikov A, Bokovaya O, et al. Isolation and characterization of a group of new Proteus bacteriophages. Arch Virol. 2018; 163(8): 2189-2197. doi: 10.1007/s00705-018-3853-3</mixed-citation><mixed-citation xml:lang="en">Morozova V, Kozlova Y, Shedko E, Babkin I, Kurilshikov A, Bokovaya O, et al. Isolation and characterization of a group of new Proteus bacteriophages. Arch Virol. 2018; 163(8): 2189-2197. doi: 10.1007/s00705-018-3853-3</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sabitova Y, Fomenko N, Tikunov A, Stronin O, Khasnatinov M, Abmed D, et al. Multilocus sequence analysis of Borrelia burgdorferi sensu lato isolates from Western Siberia, Russia and Northern Mongolia. Infect Genet Evol. 2018; 62: 160-169. doi: 10.1016/j.meegid.2018.04.015</mixed-citation><mixed-citation xml:lang="en">Sabitova Y, Fomenko N, Tikunov A, Stronin O, Khasnatinov M, Abmed D, et al. Multilocus sequence analysis of Borrelia burgdorferi sensu lato isolates from Western Siberia, Russia and Northern Mongolia. Infect Genet Evol. 2018; 62: 160-169. doi: 10.1016/j.meegid.2018.04.015</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019; 53(1): 16-21. doi: 10.1016/j.ijantimicag.2018.09.004</mixed-citation><mixed-citation xml:lang="en">Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019; 53(1): 16-21. doi: 10.1016/j.ijantimicag.2018.09.004</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Moelling K, Broecker F, Willy C. A wake-up call: we need phage therapy now. Viruses. 2018; 10(12): 688. doi: 10.3390/</mixed-citation><mixed-citation xml:lang="en">Moelling K, Broecker F, Willy C. A wake-up call: we need phage therapy now. Viruses. 2018; 10(12): 688. doi: 10.3390/v10120688</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">v10120688</mixed-citation><mixed-citation xml:lang="en">Sohail M, Latif Z. Prevalence and antibiogram of methicillin resistant Staphylococcus aureus isolated from medical devicerelated infections; a retrospective study in Lahore, Pakistan. Revista da Sociedade Brasileira de Medicina Tropical. 2017; 50(5): 680-684. doi: 10.1590/0037-8682-0352-2016</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sohail M, Latif Z. Prevalence and antibiogram of methicillin resistant Staphylococcus aureus isolated from medical devicerelated infections; a retrospective study in Lahore, Pakistan. Revista da Sociedade Brasileira de Medicina Tropical. 2017; 50(5): 680-684. doi: 10.1590/0037-8682-0352-2016</mixed-citation><mixed-citation xml:lang="en">Leung F, Richards CJ, Garbuz DS, Masri BA, Duncan CP. Two-stage total hip arthroplasty: How often does it control methicillin-resistant infection? Clin Orthop Relat Res. 2011; 469(4): 1009-1015. doi: 10.1007/s11999-010-1725-6</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Leung F, Richards CJ, Garbuz DS, Masri BA, Duncan CP. Two-stage total hip arthroplasty: How often does it control methicillin-resistant infection? Clin Orthop Relat Res. 2011; 469(4): 1009-1015. doi: 10.1007/s11999-010-1725-6</mixed-citation><mixed-citation xml:lang="en">Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH. Periprosthetic infection due to resistant staphylococci: Serious problems on the horizon. Clin Orthop Relat Res. 2009; 467(7): 1732-1739. doi: 10.1007/s11999-009-0857-z</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH. Periprosthetic infection due to resistant staphylococci: Serious problems on the horizon. Clin Orthop Relat Res. 2009; 467(7): 1732-1739. doi: 10.1007/s11999-009-0857-z</mixed-citation><mixed-citation xml:lang="en">Santoso A, Anwar IB, Sibarani TS, Soetjahjo B, Yoon TR, Park K, et al. The results of two-stage revision for methicillinresistant periprosthetic joint infection (PJI) of the hip. Orthop J Sports Med. 2020; 8(5): 18-23. doi: 10.5704/MOJ.2003.003</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Santoso A, Anwar IB, Sibarani TS, Soetjahjo B, Yoon TR, Park K, et al. The results of two-stage revision for methicillinresistant periprosthetic joint infection (PJI) of the hip. Orthop J Sports Med. 2020; 8(5): 18-23. doi: 10.5704/MOJ.2003.003</mixed-citation><mixed-citation xml:lang="en">Abdelaziz H, Grüber H, Gehrke T, Salber J, Citak M. What are the factors associated with re-revision after one-stage revision for periprosthetic joint infection of the hip? A case-control study. Clin Orthop Relat Res. 2019; 477(10): 2258-2263. doi: 10.1097/CORR.0000000000000780</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelaziz H, Grüber H, Gehrke T, Salber J, Citak M. What are the factors associated with re-revision after one-stage revision for periprosthetic joint infection of the hip? A case-control study. Clin Orthop Relat Res. 2019; 477(10): 2258-2263. doi: 10.1097/CORR.0000000000000780</mixed-citation><mixed-citation xml:lang="en">Zahar A, Klaber I, Gerken AM, Gehrke T, Gebauer M, Lausmann C, et al. Ten-year results following one-stage septic hip exchange in the management of periprosthetic joint infection. J Arthroplasty. 2019; 34(6): 1221-1226. doi: 10.1016/j.arth.2019.02.021</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zahar A, Klaber I, Gerken AM, Gehrke T, Gebauer M, Lausmann C, et al. Ten-year results following one-stage septic hip exchange in the management of periprosthetic joint infection. J Arthroplasty. 2019; 34(6): 1221-1226. doi: 10.1016/j.arth.2019.02.021</mixed-citation><mixed-citation xml:lang="en">Zeller V, Lhotellier L, Marmor S, Leclerc P, Krain A, Graff W, et al. One-stage exchange arthroplasty for chronic periprosthetic hip infection: Results of a large prospective cohort study. JBJS. 2014; 96(1): e1. doi: 10.2106/JBJS.L.01451</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zeller V, Lhotellier L, Marmor S, Leclerc P, Krain A, Graff W, et al. One-stage exchange arthroplasty for chronic periprosthetic hip infection: Results of a large prospective cohort study. JBJS. 2014; 96(1): e1. doi: 10.2106/JBJS.L.01451</mixed-citation><mixed-citation xml:lang="en">Petrova NV. Evidence-based diagnosis of implant-associated infection in orthopedic surgery. Spine Surgery. 2012; 1: 74-83. (In Russ.). doi: 10.14531/ss2012.1.74-83</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Петрова Н.В. Диагностика имплант-ассоциированных инфекций в ортопедии с позиции доказательной медицины. Хирургия позвоночника. 2012; 1: 74-83. doi: 10.14531/ss2012.1.74-83</mixed-citation><mixed-citation xml:lang="en">Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: Current concepts and outlook. EFORT Open Rev. 2019; 4(7): 482-494. doi: 10.1302/2058-5241.4.180092</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: Current concepts and outlook. EFORT Open Rev. 2019; 4(7): 482-494. doi: 10.1302/2058-5241.4.180092</mixed-citation><mixed-citation xml:lang="en">Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007; 5(1): 48-56. doi: 10.1038/nrmicro1557</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007; 5(1): 48-56. doi: 10.1038/nrmicro1557</mixed-citation><mixed-citation xml:lang="en">Gefen O, Balaban NQ. The importance of being persistent: Heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol. Rev. 2009; 33(4): 704-717. doi: 10.1111/j.1574-6976.2008.00156.x</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gefen O, Balaban NQ. The importance of being persistent: Heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol. Rev. 2009; 33(4): 704-717. doi: 10.1111/j.1574-6976.2008.00156.x</mixed-citation><mixed-citation xml:lang="en">Bigger JW. Treatment of Staphylococcal infections with penicillin by intermittent sterilization. Lancet. 1944; 244(6320): 497-500. doi: 10.1016/S0140-6736(00)74210-3</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Bigger JW. Treatment of Staphylococcal infections with penicillin by intermittent sterilization. Lancet. 1944; 244(6320): 497-500. doi: 10.1016/S0140-6736(00)74210-3</mixed-citation><mixed-citation xml:lang="en">Balaban NQ, Gerdes K, Lewis K, McKinney J. A problem of persistence: Still more questions than answers? Nature Rev Microbiol. 2013; 11(8): 587-591. doi: 10.1038/nrmicro3076</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Balaban NQ, Gerdes K, Lewis K, McKinney J. A problem of persistence: Still more questions than answers? Nature Rev Microbiol. 2013; 11(8): 587-591. doi: 10.1038/nrmicro3076</mixed-citation><mixed-citation xml:lang="en">Lewis K. Persister cells. Annu Rev Microbiol. 2010; 64(1): 357-372. doi: 10.1146/annurev.micro.112408.134306</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis K. Persister cells. Annu Rev Microbiol. 2010; 64(1): 357-372. doi: 10.1146/annurev.micro.112408.134306</mixed-citation><mixed-citation xml:lang="en">Fenton M, McAuliffe O, O’Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs. 2010; 1(1): 9-16. doi: 10.4161/bbug.1.1.9818</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Fenton M, McAuliffe O, O’Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs. 2010; 1(1): 9-16. doi: 10.4161/bbug.1.1.9818</mixed-citation><mixed-citation xml:lang="en">Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase. Microbiology. 1998; 144(11): 3039-3047. doi: 10.1099/00221287-144-11-3039</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase. Microbiology. 1998; 144(11): 3039-3047. doi: 10.1099/00221287-144-11-3039</mixed-citation><mixed-citation xml:lang="en">Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase. Microbiology. 1998; 144(11): 3039-3047. doi: 10.1099/00221287-144-11-3039</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
